Related Experiment Video

Updated: Aug 19, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Administration of prostaglandin E1 in neonates with critical congenital cardiac defects

A B Lewis, M Takahashi, P R Lurie

    The Journal of Pediatrics
    |September 1, 1978
    PubMed

    Insights

    Prostaglandin E1 effectively stabilizes critically ill neonates with ductus-dependent congenital heart defects. This medication improved blood flow and oxygen levels in infants reliant on a persistent ductus arteriosus.

    Area of Science:

    • Neonatal Cardiology
    • Pediatric Pharmacology
    • Congenital Heart Disease

    Background:

    • Persistent patency of the ductus arteriosus is critical for blood flow in certain congenital heart lesions.
    • Neonates with ductus-dependent lesions require immediate intervention for survival.

    Purpose of the Study:

    • To evaluate the efficacy and safety of Prostaglandin E1 (PGE1) in neonates and young infants with ductus-dependent congenital cardiac lesions.
    • To assess the impact of PGE1 on pulmonary and systemic blood flow in this vulnerable population.

    Main Methods:

    • PGE1 was administered to 12 neonates and young infants.
    • Patient response was monitored based on physiological parameters like arterial oxygenation, blood pressure, perfusion, and urine output.

    Main Results:

    • Nine out of twelve neonates responded favorably to PGE1 infusion, with a mean age of 2.8 days.
    • Neonates with right ventricular outflow obstruction showed a 136% mean increase in arterial PO2.
    • Systemic flow improvement was observed in ductus-dependent patients, with enhanced blood pressure, perfusion, and urine output.

    Conclusions:

    • Prostaglandin E1 is a highly effective agent for stabilizing critically ill neonates with ductus-dependent congenital cardiac lesions.
    • While side effects like pyrexia and vasodilatation can occur, they are generally reversible.
    • PGE1 offers a crucial therapeutic option for managing complex congenital heart disease in early infancy.

    More Related Videos

    Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography09:31

    Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

    Published on: January 27, 2023

    A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn11:27

    A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

    Published on: April 7, 2023

    Related Concept Videos

    Local Anesthetics: Clinical Application as Epidural Anesthesia01:29

    Local Anesthetics: Clinical Application as Epidural Anesthesia

    Epidural anesthetics are administered in the fat-filled epidural space, the outermost part of the spinal canal. This technique is commonly employed for pain management and anesthesia during lower abdomen and pelvis surgeries or labor and delivery.
    Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

    Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

    The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
    Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...